Medical Cannabis for Multiple Sclerosis UK

Evidence Note: Evidence strength varies by condition. Chronic pain and epilepsy have the strongest clinical evidence base. Other conditions are treated based on specialist clinical judgement and emerging research. All prescriptions require specialist assessment.

Multiple Sclerosis in the UK

Multiple sclerosis (MS) is a chronic, immune-mediated neurological condition affecting approximately 130,000 people in the UK — one of the highest rates in the world. MS most commonly presents between the ages of 20 and 40, with a 2:1 female predominance. Spasticity — involuntary muscle stiffness and spasms — affects up to 84% of patients and is one of the areas where medical cannabis has the most robust clinical support.

Nabiximols (Sativex): The Only MHRA-Licensed Cannabis Medicine

Sativex (nabiximols) is an oromucosal spray delivering an approximately 1:1 ratio of THC to CBD per spray. It is the only cannabis-based medicine with a full MHRA product licence in the UK, specifically indicated for moderate-to-severe spasticity in adults with MS who have not responded adequately to other anti-spasmodic medicines. The approval is supported by the Phase III SAVANT clinical programme, which demonstrated statistically significant improvements in spasticity scores versus placebo. NICE guidance (NG220) includes a conditional recommendation for nabiximols in this indication.

Beyond Sativex: Unlicensed Cannabis-Based Medicines for MS

Specialist MS neurologists and pain physicians can also prescribe unlicensed cannabis-based medicines on a named-patient basis, allowing access to EU-GMP certified dried flower, full-spectrum oils, and capsule formulations with different cannabinoid ratios:

Spasticity and muscle spasms — Balanced THC:CBD formulations are most commonly employed.
Neuropathic pain — Both central demyelinating pain and peripheral sensitisation in MS respond to cannabinoid analgesia.
Sleep disturbance — THC has well-documented sedative properties that may benefit sleep architecture in MS patients.
Bladder dysfunction — Pilot data suggest cannabinoids may reduce bladder overactivity and urgency incontinence in MS.

MS Society Position

The MS Society UK supports the use of cannabis-based medicines for appropriate MS patients within a regulated prescribing framework. Their 2019 guidance acknowledged the evidence for spasticity and called for improved NHS access. Observational data from UK MS neurology practice confirms that a meaningful proportion of patients who fail first-line anti-spasmodics experience clinically significant benefit from cannabis-based medicines.

Frequently Asked Questions

Is medical cannabis approved for MS in the UK?

Yes. Nabiximols (Sativex), an oromucosal spray containing a standardised 1:1 THC:CBD extract, is the only MHRA-licensed cannabis-based medicine in the UK, specifically approved for moderate-to-severe spasticity in adults with multiple sclerosis.

What MS symptoms can medical cannabis help with?

The strongest evidence exists for spasticity and neuropathic pain. Observational data also suggests benefit for sleep quality, bladder overactivity, tremor, and fatigue.

Can I get Sativex on the NHS for MS?

NICE recommends Sativex for moderate-to-severe spasticity in adults with MS who have not responded adequately to other anti-spasmodic medicines. However, NHS availability varies by Integrated Care Board.

Are there EU-GMP cannabis products for MS beyond Sativex?

Yes. A range of EU-GMP certified dried flower, oil, and capsule formulations can be prescribed on a named-patient basis by specialists for MS-related symptoms including pain, sleep, and bladder dysfunction.